Clinical

Dataset Information

0

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400


ABSTRACT: Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose. Approximately 460 adult participants with NSCLC, gastroesophageal adenocarcinoma/gastroesophagel junction adenocarcinoma (GEA) and colorectal cancer (CRC) or advanced solid tumors, will be enrolled in the study in approximately 7-10 sites in the Dose Escalation phase and 85-95 sites in the Dose Expansion phase worldwide. In the dose expansion arms, participants in the following advanced solid tumor indications: non-squamous NSCLC with wildtype EGFR-expression (wtEGFR NSCLC) (Part 2i) or mutated EGFR-expression (mutEGFR NSCLC) (Part 2ii), squamous NSCLC (Part 2iii), GEA [Part 3] will receive intravenous (IV) ABBV-400 monotherapy, participants CRC will receive intravenous (IV) ABBV-400 monotherapy in expansion [Part 4], and participants MET amplification will receive intravenous (IV) ABBV-400 monotherapy in expansion [Part 5]. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

DISEASE(S): Adenocarcinoma,Gastroesophageal Adenocarcinoma,Non-small Cell Lung Cancer,Advanced Solid Tumors,Colorectal Cancer,Non Small Cell Lung Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung

PROVIDER: 2388532 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2235325 | ecrin-mdr-crc
2021-01-31 | GSE144326 | GEO
| 115222 | ecrin-mdr-crc
| 2295725 | ecrin-mdr-crc
| 2353988 | ecrin-mdr-crc
| 2279951 | ecrin-mdr-crc
| 7434 | ecrin-mdr-crc
| 2140963 | ecrin-mdr-crc
2023-07-11 | BIOMD0000001074 | BioModels
| 2390967 | ecrin-mdr-crc